Angela M Haeny1, Ralitza Gueorguieva2, LaTrice Montgomery3, Krysten W Bold2, Lisa M Fucito4, Ran Wu2, Srinivas B Muvvala2, Allen Zweben5, Stephanie S O'Malley4. 1. Yale School of Medicine, Department of Psychiatry, New Haven, CT 06511, United States. Electronic address: angela.haeny@yale.edu. 2. Yale School of Medicine, Department of Psychiatry, New Haven, CT 06511, United States. 3. University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, Cincinnati, OH 45221, United States. 4. Yale School of Medicine, Department of Psychiatry, New Haven, CT 06511, United States; Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven Hospital, New Haven, CT 06511, United States. 5. Columbia University, School of Social Work, New York, NY 10027, United States.
Abstract
INTRODUCTION: Varenicline is an FDA-approved medication for smoking cessation and has demonstrated promise in reducing alcohol use. This study sought to compare the efficacy of varenicline in reducing smoking and drinking among Black and White people seeking alcohol treatment. METHODS: Linear mixed modeling was conducted using data from two multi-site placebo-controlled randomized clinical trials examining the effects of varenicline for treatment of Alcohol Use Disorder (AUD; O'Malley et al., 2018; Litten et al., 2013) among Black and White adults with AUD and co-occurring cigarette smoking. The primary analyses were conducted in a sample of 117 adults (O'Malley trial: 29.1% female, 55.2% Black), and replicated in an independent sample of 73 adults (Litten trial: 23.3% female, 45.2% Black). RESULTS: Black participants smoked fewer cigarettes per day compared to White participants (O'Malley trial: F1,116 = 8.95, p = .003; Litten trial: F1,68.9 = 4.74p = .03). Linear mixed models revealed a marginal effect of varenicline on reducing cigarettes smoked per day regardless of race in the O'Malley trial (F1,109 = 3.34, p = .07), which was replicated in the Litten trial (F1,67.1 = 20.77p < .0001). Participants reduced the number of drinks consumed regardless of treatment condition or race in both trials (O'Malley trial: F1,98 = 131.69, p < .0001; Litten trial:F1,69 = 60.36, p < .0001). CONCLUSIONS: Our adjusted model findings suggest varenicline reduced smoking among Black and White people with AUD and co-occurring cigarette smoking. However, these findings should be replicated in a larger sample.
INTRODUCTION: Varenicline is an FDA-approved medication for smoking cessation and has demonstrated promise in reducing alcohol use. This study sought to compare the efficacy of varenicline in reducing smoking and drinking among Black and White people seeking alcohol treatment. METHODS: Linear mixed modeling was conducted using data from two multi-site placebo-controlled randomized clinical trials examining the effects of varenicline for treatment of Alcohol Use Disorder (AUD; O'Malley et al., 2018; Litten et al., 2013) among Black and White adults with AUD and co-occurring cigarette smoking. The primary analyses were conducted in a sample of 117 adults (O'Malley trial: 29.1% female, 55.2% Black), and replicated in an independent sample of 73 adults (Litten trial: 23.3% female, 45.2% Black). RESULTS: Black participants smoked fewer cigarettes per day compared to White participants (O'Malley trial: F1,116 = 8.95, p = .003; Litten trial: F1,68.9 = 4.74p = .03). Linear mixed models revealed a marginal effect of varenicline on reducing cigarettes smoked per day regardless of race in the O'Malley trial (F1,109 = 3.34, p = .07), which was replicated in the Litten trial (F1,67.1 = 20.77p < .0001). Participants reduced the number of drinks consumed regardless of treatment condition or race in both trials (O'Malley trial: F1,98 = 131.69, p < .0001; Litten trial:F1,69 = 60.36, p < .0001). CONCLUSIONS: Our adjusted model findings suggest varenicline reduced smoking among Black and White people with AUD and co-occurring cigarette smoking. However, these findings should be replicated in a larger sample.
Authors: Dennis R Trinidad; Eliseo J Pérez-Stable; Martha M White; Sherry L Emery; Karen Messer Journal: Am J Public Health Date: 2011-02-17 Impact factor: 9.308
Authors: Kriti D Gandhi; Meghna P Mansukhani; Victor M Karpyak; Terry D Schneekloth; Zhen Wang; Bhanu Prakash Kolla Journal: J Clin Psychiatry Date: 2020-02-25 Impact factor: 4.384
Authors: Timothy B Baker; Megan E Piper; James H Stein; Stevens S Smith; Daniel M Bolt; David L Fraser; Michael C Fiore Journal: JAMA Date: 2016-01-26 Impact factor: 56.272
Authors: Robert West; A Eden Evins; Neal L Benowitz; Cristina Russ; Thomas McRae; David Lawrence; Lisa St Aubin; Alok Krishen; Melissa C Maravic; Robert M Anthenelli Journal: Addiction Date: 2018-03-30 Impact factor: 6.526